LSL Pharma GroupTSXV:LSL 49 PB Ratio is 1.68 as of Jun. 25, 2026, which is 34% below its 10-year median of 2.53. GuruFocus rates TSXV:LSL with a GF Score™ of 49/100 and a GF Value™ of C$0.72 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, LSL Pharma Group ranks better than 54.99% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), LSL Pharma Group's share price is C$0.32. LSL Pharma Group's Book Value per Share for the quarter that ended in Mar. 2026 was C$0.19. Hence, LSL Pharma Group's PB Ratio of today is 1.68.
Good Sign:
LSL Pharma Group Inc stock PB Ratio (=1.68) is close to 1-year low of 1.64.
The historical rank and industry rank for LSL Pharma Group's PB Ratio or its related term are showing as below:
TSXV:LSL'
s PB Ratio Range Over the Past 10 Years
Min: 1.47 Med: 2.53 Max: 14.06
Current: 1.68
During the past 6 years, LSL Pharma Group's highest PB Ratio was 14.06. The lowest was 1.47. And the median was 2.53.
TSXV:LSL's PB Ratio is ranked better than 54.99% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs TSXV:LSL: 1.68
During the past 12 months, LSL Pharma Group's average Book Value Per Share Growth Rate was -10.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 49.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 19.20% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of LSL Pharma Group was 49.30% per year. The lowest was 4.90% per year. And the median was 16.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
LSL Pharma Group PB Ratio Related Terms
LSL Pharma Group PB Ratio Historical Data
* Premium members only.
The historical data trend for LSL Pharma Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LSL Pharma Group PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where LSL Pharma Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
LSL Pharma Group (TSXV:LSL) has a PB Ratio of 1.68 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on LSL Pharma Group and its competitors. This is 34% below median its historical median of 2.53. Over the past decade, LSL Pharma Group's PB Ratio has ranged from 1.47 to 14.06. According to the industry distribution chart, LSL Pharma Group ranks #415 out of 922 companies in the Drug Manufacturers industry, placing it in the top 45%.
Is LSL Pharma Group's PB Ratio too high?
LSL Pharma Group's current PB Ratio of 1.68 is 34% below median its 10-year median of 2.53. Over the past 10 years, this metric has ranged from a low of 1.47 to a high of 14.06. The Drug Manufacturers industry median PB Ratio is 1.86. LSL Pharma Group's value of 1.68 is 9.4% below this industry median. Based on the distribution chart, LSL Pharma Group ranks #415 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, LSL Pharma Group has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, LSL Pharma Group ranks #415 out of 922 companies for PB Ratio. This puts LSL Pharma Group in the upper half of its industry. The industry median PB Ratio is 1.86. LSL Pharma Group's value of 1.68 is 9.4% below this benchmark. Historically, LSL Pharma Group's own PB Ratio has ranged from 1.47 to 14.06 over the past decade. While the company's 10-year median is 2.53 vs. the industry median of 1.86, LSL Pharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LSL Pharma Group's current PB Ratio of 1.68 is 9.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on LSL Pharma Group and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LSL Pharma Group's current PB Ratio is 1.68, which is 34% below median its own 10-year median of 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.72, compared to a current price of C$0.32 — trading 55.6% below its estimated fair value. The current PB Ratio is 1.68, which is 34% below median its 10-year median of 2.53 and 9.4% below the Drug Manufacturers industry median of 1.86. LSL Pharma Group's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current PB Ratio is 1.68 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?
Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued.
The current stock price of C$0.32 is trading 55.6% below its estimated GF Value™ of C$0.72.
GuruFocus considers LSL Pharma Group to be Possible Value Trap.
Key valuation signals for TSXV:LSL:
PB Ratio: 1.68 (34% below median its 10-year median of 2.53)
GF Value™: C$0.72 vs. price of C$0.32 (55.6% below fair value)
Industry Position: 9.4% below the Drug Manufacturers median (#415 of 922)
No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
49GF Score
Get the complete analysis for TSXV:LSL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:LSL has been successfully added to your 
